Glycation: A new hope in targeting hepatocellular carcinoma?

Abstract

Hepatocellular carcinoma (HCC) is the second most common cause of cancer mortality worldwide and is the most rapidly growing indication for liver transplantation globally. There is, therefore, an urgent need to explore novel areas which may be contributing to pathogenesis such as advanced glycation pathways, to better understand HCC progression. Advanced glycation end-products (AGEs) are a group of biologically active compounds that are formed when sugar moieties react non-enzymatically with amino groups. They are abundant in Western diets and found endogenously at an increased rate in diabetes. This article will summarise the association between AGEs in liver disease and HCC progression. In..